Stratification and selection of therapies to improve survival in severe alcoholic hepatitis

Table 3 Plasma exchange in Severe alcoholic hepatitis

Ref.	Inclusion	Exclusion criteria	Survival at day 90 in intervention group
Kumar et al[24]	APASL defined alcohol ACLF	Liver illness due to other causes (such as drug- or virus-induced hepatitis, Wilson's disease, autoimmune hepatitis, or nonalcoholic fatty liver disease), sepsis, bleeding that has occurred recently (within the last three months), cancer, acute pancreatitis, or human immunodeficiency virus infection	35.6%
Kumar et al[24]	EASL defined ACLF	Hepatocellular cancer, patients with PLEX contraindications, such as infection, recent gastrointestinal bleeding, and hypotension	70% with centrifugal plasma exchange
Ramakrishnan et al[23]	ACLF defined by APASL with AARC score 8-10 and not responding to medical therapy	Nonalcoholic etiologies, coexisting hepatocellular carcinoma or extra-hepatic malignancy, bleeding, pregnancy, multiorgan failure (≥ 3 organ failures), severe pre-existing cardiopulmonary disease, APASL-AARC score > 10 or < 8, mechanically ventilated and requiring inotropic support at the time of enrolment were excluded from the study.	64%

APASL: Asian pacific association for study of liver; AARC: Asian pacific association for study of liver acute on chronic liver failure research consortium; EASL: European association for study of the liver; ACLF: Acute on chronic liver failure.